Tiny RNA Molecule May Restore Drug Sensitivity in Resistant Prostate Tumors
Researchers at Fred Hutch Cancer Center found that a specific transfer RNA, tRNA1Arg(UCU), can influence prostate cancer cell identity and treatment response. In experimental models, restoring this molecule made treatment-resistant tumors sensitive to androgen receptor-targeting drugs again. Published in Nature, the work suggests tRNAs may actively shape cancer biology rather than play only a bystander role.
Prostate cancer is among the most common cancers in men. Many treatments aim at the androgen receptor, a protein that drives tumor growth. When tumors rely less on this receptor, they can become more aggressive and harder to treat.
Working with cell lines, mouse models, and patient samples, Fred Hutch scientists linked a specific tRNA, tRNA1Arg(UCU), to androgen-receptor dependence. It was plentiful in receptor-dependent cancers and scarce in resistant ones. Adding it back restored drug sensitivity in experimental resistant tumors. The Nature study suggests tRNAs can help determine cancer cell state, not merely support protein production.
If confirmed in further studies, this finding could affect men with treatment-resistant prostate cancer by pointing toward ways to extend the usefulness of existing androgen-receptor drugs. Clinicians may gain another marker for identifying aggressive tumors, while researchers and drug developers could explore tRNA-directed strategies. Benefits remain uncertain, and any clinical application would likely take years of testing. The broader public impact may be limited to cancer care and biomedical research rather than immediate changes in everyday medicine.